Patrick Williams
Overview
Explore the profile of Patrick Williams including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
883
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lizzio-Wilson M, Thomas E, Wenzel M, Haines E, Stevens J, Fighera D, et al.
Br J Soc Psychol
. 2025 Feb;
64(2):e12853.
PMID: 39898497
When people think of a utopian future, what do they imagine? We examined (a) whether people's self-generated utopias differ by how much they criticize, seek to change or escape from...
2.
Galsky M, Kockx M, Roels J, Van Elzen R, Guan X, Yuen K, et al.
Cancer Immunol Res
. 2025 Jan;
PMID: 39853278
Testing for PD-L1 expression by immunohistochemistry (IHC) is used to predict immune checkpoint blockade (ICB) benefit but has performed inconsistently in urothelial cancer (UC) clinical trials. Different approaches are used...
3.
Hamidi H, Senbabaoglu Y, Beig N, Roels J, Manuel C, Guan X, et al.
Cancer Cell
. 2024 Nov;
42(12):2098-2112.e4.
PMID: 39577421
Checkpoint inhibitors targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) have revolutionized cancer therapy across many indications including urothelial carcinoma (UC). Because many patients do not benefit, a...
4.
Padden-Modi M, Rush H, Abdel-Aty H, Matheson D, Millman R, Williams P, et al.
Eur Urol Oncol
. 2024 Aug;
7(5):990-992.
PMID: 39168780
Enhancement of the participant experience in quality of life (QOL) research is imperative to improve recruitment and ongoing engagement in QOL studies. Implementation of recommendations made by the patient and...
5.
Burotto M, Zvirbule Z, Alvarez R, Chewaskulyong B, Herraez-Baranda L, Shearer-Kang E, et al.
J Thorac Oncol
. 2024 May;
19(10):1460-1466.
PMID: 38729426
Introduction: Subcutaneous atezolizumab is approved for the treatment of various solid tumors. Previous results from the IMscin001 study (NCT03735121) revealed that the pharmacokinetics, efficacy, immunogenicity, and safety of subcutaneous and...
6.
Galsky M, Guan X, Rishipathak D, Rapaport A, Shehata H, Banchereau R, et al.
Cell Rep Med
. 2024 Jan;
5(2):101393.
PMID: 38280376
In metastatic urothelial cancer (mUC), cisplatin versus carboplatin leads to durable disease control in a subset of patients. The IMvigor130 trial reveals more favorable effects with atezolizumab combined with gemcitabine...
7.
Koller P, Baran N, Harutyunyan K, Cavazos A, Mallampati S, Chin R, et al.
J Immunother Cancer
. 2023 Oct;
11(10).
PMID: 37793852
Immunotherapy, in the form of hematopoietic stem cell transplantation (HSCT), has been part of the standard of care in the treatment of acute leukemia for over 40 years. Trials evaluating...
8.
Drakaki A, Powles T, Bamias A, Martin-Liberal J, Shin S, Friedlander T, et al.
Clin Cancer Res
. 2023 Aug;
29(21):4373-4384.
PMID: 37651261
Purpose: The MORPHEUS platform was designed to identify early efficacy signals and evaluate the safety of novel immunotherapy combinations across cancer types. The phase Ib/II MORPHEUS-UC trial (NCT03869190) is evaluating...
9.
Huseni M, Wang L, Klementowicz J, Yuen K, Breart B, Orr C, et al.
Cell Rep Med
. 2023 Jan;
4(1):100878.
PMID: 36599350
Although immune checkpoint inhibitors (ICIs) are established as effective cancer therapies, overcoming therapeutic resistance remains a critical challenge. Here we identify interleukin 6 (IL-6) as a correlate of poor response...
10.
Powles T, Yuen K, Gillessen S, Kadel 3rd E, Rathkopf D, Matsubara N, et al.
Nat Med
. 2022 Jan;
28(1):144-153.
PMID: 35013615
Early clinical data indicate that some patients with castration-resistant prostate cancer may benefit from program death ligand-1 (PD-L1) inhibition, especially with enzalutamide. The IMbassador250 trial (no. NCT03016312) enrolled 759 men...